Zepbound is unique because it acts on two gut hormones (GLP-1 and GIP), offering additional benefits
Patients with history of pancreatitis, severe gastrointestinal disease, or other conditions should discuss risks with their healthcare provider
US pharma giant Pfizer (NYSE: PFE) presented detailed results from multiple Phase IIb studies of berobenatide (PF-3944), an investigational, potential first-in-class monthly GLP-1 receptor agonist (GLP-1 RA) peptide, during a late-breaking expert symposium at the 86th Scientific Sessions of the American Diabetes Association (ADA)
Our clinical team already knows your history and can assess your eligibility quickly
Disease Treatment In most studies discussed below, it is important to note that treatment with L-carnitine or acyl-L-carnitine esters (i.e., acetyl-L-carnitine [ALCAR], propionyl-L-carnitine
Funded by Novo Nordisk | ClinicalTrials.gov: NCT04822181 nejm.org/doi/full/10.10 #MASH #NASH #GLP1 #ObesityMedicine #Semaglutide #MetabolicHealth #LiverDisease #Hepatology #NEJM @novonordisk Please PLEASE rebrand Wegovy for MASH so my insurance will cover it
